Form 4: Recursion Pharmaceuticals Director Franziska Michor Reports Share and Option Acquisitions Following Exscientia Acquisition

Director Franziska Michor reported acquiring shares and options in Recursion Pharmaceuticals following the acquisition of Exscientia.

Summary

• Franziska Michor, a director at Recursion Pharmaceuticals, reported several transactions on November 20, 2024, related to the acquisition of Exscientia.
• These transactions include the acquisition of 30,618 shares of Class A Common Stock in exchange for Exscientia shares.
• Michor also received 15,335, 17,694, and 41,390 restricted stock units (RSUs) that will vest over time.
• Additionally, Michor acquired stock options with various exercise prices and vesting schedules, totaling 146,431 options.
• The options and RSUs were received in exchange for Exscientia options and shares as part of the acquisition.

Sentiment

Score: 7

Explanation: The document reflects a positive event (acquisition) and standard insider transactions. The sentiment is neutral to positive as it indicates the director's increased stake in the company.

Positives

• The acquisition of Exscientia resulted in the director receiving a significant number of shares and options in Recursion.
• The vesting schedules of the RSUs and options provide long-term incentives for the director.
• The director's increased stake in Recursion aligns her interests with the company's success.

Risks

• The value of the acquired shares and options is subject to market fluctuations.
• The vesting of RSUs and options is contingent on the director's continued service with the company.

Future Outlook

The director's holdings will vest over time, subject to continued service with the company.

Industry Context

This filing reflects the completion of a significant acquisition in the biotechnology sector, where companies often use stock and options as part of deal structures and compensation.

Comparison to Industry Standards

• The use of stock options and restricted stock units is a common practice in the biotech industry for incentivizing directors and employees.
• The vesting schedules are typical for such awards, aligning with industry standards for long-term incentives.
• The acquisition of Exscientia by Recursion is a strategic move, similar to other mergers and acquisitions in the pharmaceutical and biotech space, such as the recent acquisition of Seagen by Pfizer.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive sign of confidence in the company.
• Employees may see the acquisition as a positive development for the company's future.

Next Steps

• The director's RSUs and options will vest over time according to their respective schedules.
• The director will continue to be subject to insider trading regulations.

Key Dates

Keywords

Recursion Pharmaceuticals, Exscientia, acquisition, stock options, restricted stock units, director, insider trading, share ownership